Remove Bioinformatics Remove Disease Remove Information
article thumbnail

Genomic score predicts patients' progression to multiple myeloma

Broad Institute

The score, called an MM-like score, assesses the severity of disease and risk of progression to active cancer, with higher scores indicating faster progression. In the future, the MM-like score could be used in clinical practice to inform decisions about early intervention. The study was published in Nature Genetics.

DNA 52
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

NGS has revolutionised genomic analysis, enabling the identification of disease-related genetic variants. This approach overcomes the limitations of traditional methods that analyse only single modalities of information. This shift is driven by open access policies to biomedical data and the advent of next-generation sequencing (NGS).

Drugs 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

It will also cover recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, the use of targeted delivery to reach disease-relevant tissues as well as success stories in bringing therapeutic oligonucleotides to the clinic.

RNA 59
article thumbnail

Case study: NCI’s Molecular Targets Platform

The Open Targets Blog

Data integration under common ontological terms will aid in categorising diseases, genes, and agents. Deanne Taylor ] The purpose of the project was to deliver harmonized genomic information to support therapeutic discovery in pediatric cancer. The

article thumbnail

Biochemical assays and deep cyclic inhibition in cancer treatment

Drug Target Review

These assays provide insights into the molecular mechanisms of disease biology and drug response, enabling the characterisation of gene expression profiles and deviations in diseased cells. Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

article thumbnail

Vitamin A and its role in psychiatric and other disorders

Drug Target Review

In other words, a disease state may cause a change in vitamin A levels rather than the vitamin A levels causing a change in disease state. Again, in this circumstance adding the vitamin will not help therapeutically with the disease state. Secondly, it’s difficult to separate causation from reverse causation.

article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs.